![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for…
![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](https://i0.wp.com/ml-eu.globenewswire.com/media/ZTQzNjcwMWUtZTZmZi00MTQ2LTk4YzEtMDM3YWJiOTVmYTcxLTEwMTQyODItMjAyNS0wNC0xNC1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US")
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely…